Skip to main content

Table 2 Characteristics of children started on antiretroviral treatment (n = 315)

From: Success with antiretroviral treatment for children in Kigali, Rwanda: Experience with health center/nurse-based care

Age at starta

7.2 (4.5 – 10.4)

   < 3 yearsb

38 (12%)

   3 – 4.9 yearsb

51 (16%)

   5 – 14.9 yearsb

226 (72%)

Sex (male/female)b

157/158 (50/50%)

Clinical WHO-stageqb

 

   WHO stage I

43 (13.7%)

   WHO stage II

145 (46.0%)

   WHO stage III

115 (36.5%)

   WHO stage IV

12 (3.8%)

Weight for age (Z-score) (n = 293)a

-1.9 (-3.0;-0.9)

Baseline CD4 count % (n = 282)a

14 (9–18)

   < 15%b

158 (56.0%)

   15–25%b

118 (41.8%)

   > 25%b

6 (2.1%)

Baseline absolute CD4 counts (n= 302)a

345 (229–572)

Baseline hemoglobin (mg/dl)(n = 268)a

11.0 (10.3–11.8)

ART regimenb

 

   d4T/3TC/NVP

281 (89.2%)

   d4T/3TC/EFV

6 (1.9%)

   AZT/3TC/NVP

19 (6.0%)

   AZT/3TC/EFV

9 (2.9%)

Time on ART (years)c

2.0 (1.2–2.6)

   Total patient years of follow-up

598

On tablets (FDC)

577

On syrup

21

   < 1 year vs. ≥ 1 yearb

59 (19 %) vs 256 (81 %)

  1. a Values are expressed as median (interquartile range)
  2. b Values are expressed as n (%)
  3. c As of June 30/2007 (closing date of dataset)
  4. WHO: world health organization; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; FDC: fixed-dose combination